Skip to main content

Table 1 Phenotypic heterogeneity in a cohort of 282 cases of psoriatic arthritis

From: Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype

Age

55 ± 12

Male gender

134 (47)

Family history of psoriasis (n = 280)

175 (63)

Family history of PsA (n = 280)

45 (16)

Age of onset of psoriasis

28 ± 14

Psoriasis duration (years)

27 ± 14

Age of onset of PsA

35 ± 13

PsA duration (years)

19 ± 9

Years between psoriasis and PsA

6 (0 to 14)

Psoriasis before PsA

184 (65)

PsA before psoriasis

45 (16)

Psoriasis and PsA at same time

52 (18)

Nail disease

244 (79)

 Pitting

96 (34)

 Onycholysis

155 (55)

Peripheral arthritis

280 (99)

 Polyarthritis

258 (91)

 Oligoarthritis

21 (8)

Deformed joint count, if deformity

6 (4 to 12)

Enthesitisa

97 (34)

Dactylitisa

150 (53)

Sacroiliitisa

71 (25)

 Asymmetrica

51 (18)

 Symmetrica

18 (6)

Joint deformitya

183 (65)

Joint fusiona

83 (29)

Erosionsa (n = 281)

123 (44)

Osteolysisa (n = 281)

41 (15)

Current PASI

1.2 (0.3 to 2.8)

Max PASI

3.8 (1.8 to 9.2)

Plaque psoriasis only

224 (79)

Psoriasis, nonplaque

59 (21)

Uveitis

9 (3)

Total on TNFi

176 (62)

 Psoriasis requiring TNFi

32 (11)

 PsA requiring TNFi

171 (60)

Number of TNFi, if on TNFi

1 (1 to 2; range 1 to 4)

Number of DMARDs

1 (1 to 2; range 0 to 5)

  1. Data presented as mean ± standard deviation or n (%). DMARD, disease-modifying antirheumatic drug; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor. aVariables used to construct the propensity score.